Melanoma & Skin Cancer | Specialty

Dr. Topalian on Biomarkers for Anti- PD-1 Therapies in Melanoma

February 12th 2015

Suzanne Topalian, MD, professor of surgery and oncology, John Hopkins Medicine, and director of the melanoma program, Sidney Kimmel Comprehensive Cancer Center, compares biomarker detection for anti- PD-1 therapies like nivolumab to anti-CTLA-4 therapies like ipilimumab for the treatment of melanoma.

Dr. Jeffrey Weber on Ipilimumab for Melanoma

February 2nd 2015

Jeffrey Weber, MD, PhD, a senior member at the Moffitt Cancer Center, discusses the EORTC 18701 study, which compared ipilimumab with placebo for patients with stage III node-positive melanoma.

Dr. Kluger on Toxicity of Nivolumab/ Ipilimumab for Advanced Melanoma

January 29th 2015

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, talks about the toxicity of nivolumab and ipilimumab for the treatment of patients with advanced melanoma.

PD-1 Inhibition: The Changing Treatment Paradigm for Melanoma

January 29th 2015

An increased understanding of tumor immunology has led to seven new melanoma drug approvals since 2011, including the recent approvals of the PD-1 inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda).

Novel VIL Approach Reduces Complications From Regional Lymphadenectomy in Melanoma

January 27th 2015

Surgical intervention is a Machiavellian endeavor: the ends justify the means. This obligates the clinician to minimize the risk of a procedure to justify the gains obtained from an intervention.

Dr. Wolchok on Remaining Questions Regarding Immunotherapies in Melanoma

January 13th 2015

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses remaining questions regarding immunotherapies for the treatment of melanoma.

Expert Discusses Integration of PD-1 Inhibitors Into Clinical Practice

January 13th 2015

To gain insight on the integration of these agents and other immunotherapies into clinical practice, OncLive interviewed Jeffery S. Weber, MD, PhD, a senior member at Moffitt Cancer Center in Tampa, Florida.

Expanded RAS Mutation Testing in mCRC

January 1st 2015

2014 Year in Review

January 1st 2015

FDA Approves Nivolumab for Advanced Melanoma

December 22nd 2014

The FDA has approved the PD-1 inhibitor nivolumab for patients with unresectable or metastatic melanoma following treatment with ipilimumab or a BRAF inhibitor.

The Evolving Treatment Landscape in Advanced Melanoma

December 18th 2014

Metastatic melanoma is associated with a poor prognosis, but recent breakthroughs in tumor biology and immune regulation have led to the development of agents that could change clinical practice.

Rosenberg's Many Breakthroughs Fueled by Passion and Hard Work

November 21st 2014

Steven Rosenberg always knew that he wanted to become a physician scientist, and he quickly advanced to become the chief of surgery at the National Cancer Institute (NCI) at just 34 years of age.

Pre-Chemo Abiraterone Extends Survival in CRPC

November 21st 2014

ADT With GnRH Antagonists in Prostate Cancer

November 21st 2014

Upcoming Advances for GU Cancers

November 21st 2014

Latest News & Insight: November 20, 2014

November 21st 2014

Nivolumab Extends Survival in Phase III Melanoma Study

November 17th 2014

Frontline treatment with nivolumab significantly extended OS and PFS compared with dacarbazine in patients with untreated BRAF wild-type advanced melanoma.

Pembrolizumab Improves PFS, ORR Versus Chemotherapy in Phase II Melanoma Study

November 16th 2014

The PD-1 inhibitor pembrolizumab significantly improved PFS by over 43% compared with chemotherapy as a treatment for patients with metastatic melanoma who were refractory to ipilimumab.

Adding GM-CSF to Ipilimumab Improves OS, Lowers Toxicity in Advanced Melanoma

November 5th 2014

The addition of the GM-CSF agent sargramostim to the CTLA-4 inhibitor ipilimumab (Yervoy) prolonged overall survival (OS) and lowered toxicity for patients with unresectable stage III or IV melanoma

New Study Links Socioeconomic Factors and Fashion Trends Over the Past Century to Increased Incidence of Melanoma

October 31st 2014

Researchers analyzed artwork, advertisements and leisure time activities to estimate historic changes in UV exposure